FTH

Faeth Therapeutics, Inc. FTH

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-16.01M

Quarter to Jun 30

Free cash flow

$-15.67M

Quarter to Jun 30

Top Institutional Holders

as of Q1 2025
$760.2K total
VANGUARD GROUP INC
$230.7K-1.5%
Ikarian Capital, LLC
$177.3K-30.8%
Catalio Capital Management, LP
$116.0K0.0%
RENAISSANCE TECHNOLOGIES LLC
$69.9K+13.1%
GEODE CAPITAL MANAGEMENT, LLC
$59.4K+1.2%
BOOTHBAY FUND MANAGEMENT, LLC
$42.8K-37.1%
UBS Group AG
$16.8KNew
NORTHERN TRUST CORP
$10.2K0.0%
STATE STREET CORP
$10.2K0.0%
Cresset Asset Management, LLC
$7.8K0.0%
NWF Advisory Services Inc.
$6.5K0.0%
RAYMOND JAMES FINANCIAL INC
$5.5K-50.0%
MORGAN STANLEY
$3.6K0.0%
Tower Research Capital LLC (TRC)
$2.1K-0.8%
BARCLAYS PLC
$1.0KNew
JPMORGAN CHASE & CO
$276-0.4%
BNP PARIBAS FINANCIAL MARKETS
$630.0%
BANK OF AMERICA CORP /DE/
$56+4.4%
CITIGROUP INC
$49New
SBI Securities Co., Ltd.
$36+29.6%
PROEQUITIES, INC.
$0New
See all 21 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FTH

Earnings Per Share

13fpro.ai/company/FTH

Loading ratio trend…

FTH insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Faeth Therapeutics, Inc. (FTH): stock profile, AI score and financials

Faeth Therapeutics, Inc. (FTH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. FTH is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Faeth Therapeutics, Inc. reports net income of $-16.0M, free cash flow of $-15.7M. Top institutional holders of FTH by reported 13-F value include VANGUARD GROUP, Ikarian Capital, Catalio Capital Management, based on the most recent SEC filings. FTH trades on the Nasdaq exchange and files with the SEC under CIK 1829802. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Faeth Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1829802 →